clinical trial · NCT00840476
Meloxicam 15 mg Tablets Under Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 28
HealthyMeloxicam 15 mg TabletsMobic® 15 mg Tablets
brief summary
The objective of this study is to compare the rate and extent of absorption of meloxicam from a test formulation Meloxicam 15 mg Tablets versus the reference Mobic® 15 mg Tablets under fasting conditions.
started
Feb 1, 2004
primary completion
Feb 1, 2004
completion
Feb 1, 2004
last updated
Aug 19, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol